CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 93 enrolled
Drug / intervention
3'-Deoxy-3'-18f-Fluorothymidine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01399658
NCT01399658Phase 2Completed
CompareCT.gov

A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO)

Dana-Farber Cancer Institute·interventional·Posted Jul 22, 2011·Updated Mar 14, 2023

In Brief

A Phase 2 clinical trial evaluating Image-guided brachytherapy and 3'-Deoxy-3'-18f-Fluorothymidine for Cervical Cancer and 3 related conditions. Completed, enrolled 93 participants across 1 site.

Detailed Summary

Standard therapy for gynecologic cancers involves the use of brachytherapy, also called internal radiation therapy or implant radiation. The treatment being studied consists of standard brachytherapy with the additional use of MRI to guide the insertion of radioactive applicators. The purpose of the study is to find out whether MRI-guided brachytherapy is practical and beneficial when compared to the standard CT-guided brachytherapy placement. The investigators are hoping that this MRI procedure will decrease the risk of giving too high a radiation dose to the bladder or bowel.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer, Uterine Cancer, Vaginal Cancer, Carcinoma of the Vulva
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 22, 2011
Enrollment StartSep 1, 2011
Primary CompletionFeb 1, 2016
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 14.9 years ago

Interventions

Image-guided brachytherapyprocedure

MRI-guided application of brachytherapy

3'-Deoxy-3'-18f-Fluorothymidinedrug

Assessing tumor proliferation in Gynecologic cancer